{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T19:33:38Z","timestamp":1784748818699,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Psoriasis frequently coexists with other immune-mediated conditions such as arthritis, alopecia areata, vitiligo, and hidradenitis suppurativa, many of which remain challenging to manage. To date, there have been rarely reported cases of treating psoriasis combined with lichen planus. We report a case of coexisting psoriasis and lichen planus in a female patient. Despite initial efficacy with acitretin and topical mometasone, the patient self-discontinued treatment over safety concerns, prompting a relapse. Upadacitinib was subsequently initiated and yielded marked improvement within 3 months. By discussing the disease interplay and treatment rationale, this report seeks to inform clinical decision-making.<\/jats:p>","DOI":"10.3389\/fmed.2026.1771710","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:13:47Z","timestamp":1776658427000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Upadacitinib is effective in treating psoriasis combined with lichen planus: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Xingmo","family":"Li","sequence":"first","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang","place":["Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases, Shijiazhuang","place":["Hebei, China"]},{"name":"Hebei Provincial Innovation Center of Dermatology and Medical Cosmetology Technology, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxu","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang","place":["Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases, Shijiazhuang","place":["Hebei, China"]},{"name":"Hebei Provincial Innovation Center of Dermatology and Medical Cosmetology Technology, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang","place":["Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases, Shijiazhuang","place":["Hebei, China"]},{"name":"Hebei Provincial Innovation Center of Dermatology and Medical Cosmetology Technology, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang","place":["Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases, Shijiazhuang","place":["Hebei, China"]},{"name":"Hebei Provincial Innovation Center of Dermatology and Medical Cosmetology Technology, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang","place":["Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases, Shijiazhuang","place":["Hebei, China"]},{"name":"Hebei Provincial Innovation Center of Dermatology and Medical Cosmetology Technology, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang","place":["Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases, Shijiazhuang","place":["Hebei, China"]},{"name":"Hebei Provincial Innovation Center of Dermatology and Medical Cosmetology Technology, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang","place":["Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases, Shijiazhuang","place":["Hebei, China"]},{"name":"Hebei Provincial Innovation Center of Dermatology and Medical Cosmetology Technology, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1007\/s00018-020-03726-1","article-title":"Immune responses and therapeutic options in psoriasis.","volume":"78","author":"Afonina","year":"2021","journal-title":"Cell Mol Life Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/bs.acc.2023.03.006","article-title":"Autoantibodies in psoriatic disease.","volume":"115","author":"Koussiouris","year":"2023","journal-title":"Adv Clin Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1001\/jamadermatol.2022.3682","article-title":"Association between inflammatory bowel disease and both psoriasis and psoriatic arthritis: a bidirectional 2-sample mendelian randomization study.","volume":"158","author":"Freuer","year":"2022","journal-title":"JAMA Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1341632","DOI":"10.3389\/fimmu.2024.1341632","article-title":"Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses.","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1432233","DOI":"10.3389\/fimmu.2024.1432233","article-title":"Case report: psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib.","volume":"15","author":"Salvi","year":"2024","journal-title":"Front Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2209920","DOI":"10.1080\/19420862.2023.2209920","article-title":"Izokibep: preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis.","volume":"15","author":"Klint","year":"2023","journal-title":"mAbs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/ddg.14565","article-title":"Lichen planus - a clinical guide.","volume":"19","author":"Solimani","year":"2021","journal-title":"J Dtsch Dermatol Ges."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1007\/s10787-025-01853-4","article-title":"A systematic review of the role of interleukin inhibitors in lichen planus: therapeutic and paradoxical effects.","volume":"33","author":"Heidari","year":"2025","journal-title":"Inflammopharmacology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaci.2022.09.023","article-title":"Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies.","volume":"151","author":"Guttman-Yassky","year":"2023","journal-title":"J Allergy Clin Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.36849\/JDD.7500","article-title":"Off-label use of janus kinase inhibitors in inflammatory cutaneous diseases.","volume":"22","author":"Agarwal","year":"2023","journal-title":"J Drugs Dermatol."},{"key":"B11","unstructured":"RINVOQ (upadacitinib): Highlights of prescribing information. U.S. Food and Drug Administration Approved Drug Products, 1-45.\n          \n          \n          2025"},{"key":"B12","doi-asserted-by":"publisher","first-page":"111373","DOI":"10.1016\/j.biopha.2021.111373","article-title":"Studies on the anti-psoriasis effects and its mechanism of a dual JAK2\/FLT3 inhibitor flonoltinib maleate.","volume":"137","author":"Zhu","year":"2021","journal-title":"Biomed Pharmacother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s12016-024-08991-7","article-title":"The immunology of psoriasis-current concepts in pathogenesis.","volume":"66","author":"Sieminska","year":"2024","journal-title":"Clin Rev Allergy Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/ced.13351","article-title":"Possible role of plasmacytoid dendritic cells in pityriasis lichenoides.","volume":"43","author":"Karouni","year":"2018","journal-title":"Clin. Exp Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"122991","DOI":"10.1016\/j.lfs.2024.122991","article-title":"Advances in psoriasis research: from pathogenesis to therapeutics.","volume":"355","author":"Sugumaran","year":"2024","journal-title":"Life Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s40257-024-00878-9","article-title":"Lichen planus: what is new in diagnosis and treatment?","volume":"25","author":"Tekin","year":"2024","journal-title":"Am J Clin Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/exd.14226","article-title":"The inflammation in cutaneous lichen planus is dominated by IFN-? and IL-21-A basis for therapeutic JAK1 inhibition.","volume":"30","author":"Pietschke","year":"2021","journal-title":"Exp Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1286776","DOI":"10.3389\/fimmu.2023.1286776","article-title":"Noval advance of histone modification in inflammatory skin diseases and related treatment methods.","volume":"14","author":"Zhang","year":"2024","journal-title":"Front Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3390\/antiox10071087","article-title":"Therapies with antioxidant potential in psoriasis, vitiligo, and lichen planus.","volume":"10","author":"Guarneri","year":"2021","journal-title":"Antioxidants."},{"key":"B20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12979-023-00400-5","article-title":"Senescence-associated secretory phenotypes in mesenchymal cells contribute to cytotoxic immune response in oral lichen planus.","volume":"20","author":"Ijima","year":"2023","journal-title":"Immun Ageing."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.jid.2025.04.043","article-title":"Single-cell profiling of lichen planus reveals type I IFN response triggering the interface dermatitis reaction.","volume":"145","author":"Grolleau","year":"2025","journal-title":"J Invest Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1111\/jdv.18263","article-title":"The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.","volume":"36","author":"Zhang","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/12034754231156100","article-title":"The use of janus kinase inhibitors for lichen planus: an evidence-based review.","volume":"27","author":"Abduelmula","year":"2023","journal-title":"J Cutan Med Surg."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1111\/jdv.19440","article-title":"Rapid and sustained improvement of cutaneous lichen planus with oral JAK1 inhibitors.","volume":"38","author":"B\u00f6ll","year":"2024","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial.","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40261-024-01382-y","article-title":"Effectiveness and safety of upadacitinib for adolescents with atopic dermatitis in a real-world setting.","volume":"44","author":"Patruno","year":"2024","journal-title":"Clin. Drug Invest."},{"key":"B28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1001\/jamadermatol.2022.0147","article-title":"Treatment of oral erosive lichen planus with upadacitinib.","volume":"158","author":"Balestri","year":"2022","journal-title":"JAMA Dermatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/ddg.14612","article-title":"Alleviation of erosive oral and esophageal lichen planus by the JAK1 inhibitor upadacitinib.","volume":"19","author":"Kooybaran","year":"2021","journal-title":"J Dtsch Dermatol Ges."},{"key":"B30","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/medicina62010190","article-title":"JAK-inhibitors beyond the label: emerging applications in dermatology.","volume":"62","author":"Foggi","year":"2026","journal-title":"Medicina."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1771710\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:13:49Z","timestamp":1776658429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1771710\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":30,"alternative-id":["10.3389\/fmed.2026.1771710"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1771710","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"1771710"}}